Autonomix Medical (AMIX) said Friday that it finalized the design of its Application Specific Integrated Circuits, or ASIC, microchip for its sensing technology catheter, following successful in vivo preclinical and bench testing.
This marks a key step toward the pivotal clinical trial of the device in the US, planned for 2025, according to the company.
The ASIC microchip is designed to facilitate nerve signal detection through vascular pathways, the company added.
Achieving this technical milestone should pave the way for commercialization of the company's Autonomix Sensing and RF Ablation System in the US as a treatment for pancreatic cancer pain, it said.
Shares of Autonomix Medical were up 8.5% in recent trading.
Price: 3.10, Change: +0.24, Percent Change: +8.53
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.